{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:54:16Z","timestamp":1774634056440,"version":"3.50.1"},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2022,8,4]]},"DOI":"10.18632\/oncotarget.28257","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T12:41:36Z","timestamp":1659616896000},"page":"970-981","source":"Crossref","is-referenced-by-count":4,"title":["Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors"],"prefix":"10.18632","volume":"13","author":[{"given":"Andliena","family":"Tahiri","sequence":"first","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Medical Genetics, Oslo University Hospital, Ullev\u00e5l, Norway"},{"name":"Department of Clinical Molecular Biology (EpiGen), Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Puco","sequence":"additional","affiliation":[{"name":"Department of Oncology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faris","family":"Naji","sequence":"additional","affiliation":[{"name":"Pamgene International BV, \u2018s-Hertogenbosch, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vessela N.","family":"Kristensen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Medical Genetics, Oslo University Hospital, Ullev\u00e5l, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenny Cecilie","family":"Alfsen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Pathology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorant","family":"Farkas","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Pathology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frode S.","family":"Nilsen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Urology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stig","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Urology, Akershus University Hospital, L\u00f8renskog, Norway"},{"name":"These authors contributed equally to this work"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Oncology, Akershus University Hospital, L\u00f8renskog, Norway"},{"name":"These authors contributed equally to this work"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Geisler","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Oncology, Akershus University Hospital, L\u00f8renskog, Norway"},{"name":"These authors contributed equally to this work"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"4","author":"Bray","year":"2013","journal-title":"Eur J Cancer"},{"key":"2","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"14","author":"Bray","year":"2019","journal-title":"Int J Cancer"},{"key":"3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00345-016-1773-y","article-title":"Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study","volume":"3","author":"Lundstam","year":"2016","journal-title":"World J Urol"},{"key":"4","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1016\/j.celrep.2018.06.032","article-title":"The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma","volume":"2","author":"Gibbs","year":"2018","journal-title":"Cell Rep"},{"key":"5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.2011-S2-04","article-title":"Tumor biology and prognostic factors in renal cell carcinoma","volume":"1","author":"Belldegrun","year":"2011","journal-title":"Oncologist"},{"key":"6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11523-013-0303-8","article-title":"New agents in renal cell carcinoma","volume":"9","author":"George","year":"2014","journal-title":"Target Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"1758835920907504","DOI":"10.1177\/1758835920907504","article-title":"Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma","volume":"1","author":"Albiges","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1582-4934.2008.00578.x","article-title":"VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma","volume":"1","author":"Mukhopadhyay","year":"2010","journal-title":"J Cell Mol Med"},{"key":"9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.semnephrol.2019.12.009","article-title":"Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma","volume":"4","author":"Bajwa","year":"2020","journal-title":"Semin Nephrol"},{"key":"10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"1","author":"Kanesvaran","year":"2015","journal-title":"Lancet Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1038\/bjc.2013.236","article-title":"Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma","volume":"10","author":"Gore","year":"2013","journal-title":"Br J Cancer"},{"key":"12","doi-asserted-by":"publisher","first-page":"e0139267","DOI":"10.1371\/journal.pone.0139267","article-title":"High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes","volume":"1","author":"Sonpavde","year":"2015","journal-title":"PLoS One"},{"key":"13","first-page":"1220","article-title":"Overexpressed gene signature of EPH receptor A\/B family in cancer patients-comprehensive analyses from the public high-throughput database","volume":"1","author":"Jiang","year":"2020","journal-title":"Int J Clin Exp Pathol"},{"key":"14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/cancers14041095","article-title":"c-Met and EPHA7 Receptor Tyrosine Kinases Are Related to Prognosis in Clear Cell Renal Cell Carcinoma: Focusing on the Association with Myoferlin Expression","volume":"1","author":"Moon","year":"2022","journal-title":"Cancers (Basel)"},{"key":"15","doi-asserted-by":"publisher","first-page":"e102262","DOI":"10.1371\/journal.pone.0102262","article-title":"Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma","volume":"9","author":"Baretton","year":"2014","journal-title":"PLoS One"},{"key":"16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/bjc.2012.314","article-title":"Expression and prognostic significance of Src family members in renal clear cell carcinoma","volume":"10","author":"Edwards","year":"2012","journal-title":"Br J Cancer"},{"key":"17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1073\/pnas.87.2.558","article-title":"Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis","volume":"8","author":"Eckhart","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"18","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/s0959-8049(03)00276-4","article-title":"pp60c-src activation in lung adenocarcinoma","volume":"3","author":"Kuriyama","year":"2003","journal-title":"Eur J Cancer"},{"key":"19","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/sj.bjc.6605829","article-title":"Breast cancer patients\u2019 clinical outcome measures are associated with Src kinase family member expression","volume":"10","author":"Edwards","year":"2010","journal-title":"Br J Cancer"},{"key":"20","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1158\/1541-7786.MCR-13-0490-T","article-title":"Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancer","volume":"1","author":"Foster","year":"2014","journal-title":"Mol Cancer Res"},{"key":"21","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.2147\/OTT.S245749","article-title":"SRC Promotes Tamoxifen Resistance in Breast Cancer via Up-Regulating SIRT1","volume":"1","author":"Huang","year":"2020","journal-title":"Onco Targets Ther"},{"key":"22","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1083\/jcb.200302073","article-title":"EphB1 recruits c-Src and p52Shc to activate MAPK\/ERK and promote chemotaxis","volume":"16","author":"Huynh-Do","year":"2003","journal-title":"J Cell Biol"},{"key":"23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"49","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"24","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1358\/dot.2017.53.11.2724804","article-title":"Tivozanib: a new treatment option for renal cell carcinoma","volume":"5","author":"Eskens","year":"2017","journal-title":"Drugs Today (Barc)"},{"key":"25","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s40265-017-0825-y","article-title":"Tivozanib: First Global Approval","volume":"7","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"26","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1200\/JCO.2021.39.15_suppl.4546","article-title":"TIVO-3: Durability of response and updated overall survival of tivozanib versus sorafenib in metastatic renal cell carcinoma (mRCC)","volume":"3","author":"Atkins","year":"2021","journal-title":"J Clin Oncol"},{"key":"27","doi-asserted-by":"publisher","first-page":"e72692","DOI":"10.1371\/journal.pone.0072692","article-title":"Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma","volume":"8","author":"Geisler","year":"2013","journal-title":"PLoS One"},{"key":"28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1034\/j.1600-065x.2003.00028.x","article-title":"GTPases and T cell activation","volume":"19","author":"Cantrell","year":"2003","journal-title":"Immunol Rev"},{"key":"29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0092-8674(89)90985-9","article-title":"A ras-related gene with transformation suppressor activity","volume":"5","author":"Noda","year":"1989","journal-title":"Cell"},{"key":"30","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1098\/rstb.2006.1894","article-title":"Neurotrophin-regulated signalling pathways","volume":"36","author":"Reichardt","year":"2006","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"31","doi-asserted-by":"publisher","first-page":"11770","DOI":"10.18632\/aging.102499","article-title":"Cancer stem cells-driven tumor growth and immune escape: the Janus face of neurotrophins","volume":"1","author":"Tirassa","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"32","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/14712598.2021.1890713","article-title":"Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma","volume":"2","author":"Bedke","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12943-018-0800-6","article-title":"Targeting tumour microenvironment by tyrosine kinase inhibitor","volume":"1","author":"Cheng","year":"2018","journal-title":"Mol Cancer"},{"key":"34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"3","author":"Katoh","year":"2016","journal-title":"Int J Mol Med"},{"key":"35","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/ijms18071527","article-title":"Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma","volume":"1","author":"Piva","year":"2017","journal-title":"Int J Mol Sci"},{"key":"36","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"48","author":"Solit","year":"2012","journal-title":"Nature"},{"key":"37","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10549-020-05763-7","article-title":"Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer","volume":"18","author":"Kristensen","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Lempicki","year":"2009","journal-title":"Nat Protoc"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T12:41:52Z","timestamp":1659616912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,8,4]]}},"alternative-id":["28257"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28257","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]}}}